Výsledky vyhledávání - "Manoj A. Jivani"

ENGINE: a Phase III randomized placebo controlled study of enzastaurin/R-CHOP as frontline therapy in high-risk diffuse large B-cell lymphoma patients with the genomic biomarker DGM1

Publikováno v: Future oncology (London, England). 16(15)

While combination of rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone (R-CHOP) cures most patients with diffuse large B-cell lymphoma (DLBCL), those with high-risk international prognostic index disease have inferior survival. Enz

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7223edfa70f0fd5d607e865bc372dd84
https://pubmed.ncbi.nlm.nih.gov/32250167

Zobrazit plný text záznamu

An Open Label Phase Ib Dose Escalation Study of TRC105 (Anti-Endoglin Antibody) with Axitinib in Patients with Metastatic Renal Cell Carcinoma

Autor: Bonne J. Adams, David F. McDermott, Charles P. Theuer, Zhenhua Yuan, Manoj A. Jivani, Guru Sonpavde, Ben K. Seon, Yingmiao Liu, Edwin M. Posadas, M. Dror Michaelson, Andrew B. Nixon, Toni K. Choueiri, Meghara K. Walsh

Publikováno v: The Oncologist. 24:202-210

Background TRC105 is an IgG1 endoglin monoclonal antibody that potentiates VEGF inhibitors in preclinical models. We assessed safety, pharmacokinetics, and antitumor activity of TRC105 in combination with axitinib in patients with metastatic renal ce

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c25dc6244e305a1a63d8ea4ff0ec75ce
https://doi.org/10.1634/theoncologist.2018-0299

Zobrazit plný text záznamu

RBTT-04. DGM1 MAY SERVE AS A NOVEL GENETIC BIOMARKER OF RESPONSE TO ENZASTAURIN IN GLIOBLASTOMA

Autor: Hong Sun, Manoj A. Jivani, Ling Li, Wen Luo, Nicholas Butowski, Lei Zhang, Isabel Han

Publikováno v: Neuro Oncol

BACKGROUND No significant progress has been made over the last decade in therapies available for glioblastoma (GBM) with survival remaining poor. Meaningful advances in treating this deadly malignancy may rely on precision medicine. A novel pharmacog

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d5b8bf4a67b07193807cc9b6da1e646c
https://europepmc.org/articles/PMC6847292/

Zobrazit plný text záznamu

Engine: Phase III Randomized Study of Enzastaurin/R-CHOP Versus Placebo/R-CHOP in Frontline High Risk Diffuse Large B Cell Lymphoma Patients with Novel Genomic Biomarker DGM1

Autor: Grzegorz S. Nowakowski, Young Liu, Qingyuan Zhang, Lei Zhang, Yongping Song, Isabel Han, Xiuhua Sun, Joseph Maly, Jennifer K. Lue, Manoj A. Jivani, J. Sun, Ling Li, Wen Luo, Jun Zhu, Joshua Brody, Stephen D. Smith, Yuqin Song

Publikováno v: Blood. 134:5330-5330

Background: Progress in genome technology allows analysis of previously completed trials to identify subgroups potentially benefiting from therapy. Enzastaurin is a potent inhibitor of protein kinase C beta (PKC-β) and suppresses the phosphoinositid

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::76e4f7b2ffa1b4a0c5b7619ee6a4944c
https://doi.org/10.1182/blood-2019-124930

Zobrazit plný text záznamu

DGM1 may serve as a novel genetic biomarker of response to enzastaurin in glioblastoma

Autor: Isabel Han, Wen Luo, Ronald L. Shazer, Hong Sun, Manoj A. Jivani, Nicholas Butowski

Publikováno v: Journal of Clinical Oncology. 37:2023-2023

2023 Background: Despite countless clinical trials being conducted, little has changed over the last decade in the chemotherapies available for glioblastoma (GBM) with survival remaining poor. Meaningful advances in treating this deadly malignancy ma

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::27dc6c8f8792dc989e9f2853f5f35f30
https://doi.org/10.1200/jco.2019.37.15_suppl.2023

Zobrazit plný text záznamu

ENGINE: Phase III randomized study of enzastaurin/R-CHOP versus placebo/R-CHOP in frontline high-risk diffuse large B-cell lymphoma patients with novel genomic biomarker DGM1

Autor: Lei Zhang, Stephen D. Smith, Isabel Han, Owen A. O'Connor, Jun Zhu, Ronald L. Shazer, Wen Luo, Grzegorz S. Nowakowski, Young Liu, Manoj A. Jivani

Publikováno v: Journal of Clinical Oncology. 37:TPS7569-TPS7569

TPS7569 Background: Progress in genome technology allows analysis of previously completed trials to identify patients subgroups potentially benefiting from therapy. Enzastaurin is a potent inhibitor of protein kinase C beta (PKC- b) and suppresses th

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::e3325977c910fe4abd87acca8c53ee99
https://doi.org/10.1200/jco.2019.37.15_suppl.tps7569

Zobrazit plný text záznamu

Biomarker modulation in patients treated with TRC105 in combination with anti-VEGF therapy

Autor: Kouros Owzar, Toni K. Choueiri, Manoj A. Jivani, Charles P. Theuer, Dadong Zhang, Zhenhua Yuan, John C. Brady, Steven Attia, Bonne J. Adams, Delia Alvarez, Andrew B. Nixon, Herbert Hurwitz, Yingmiao Liu, Mark D. Starr

Publikováno v: Journal of Clinical Oncology. 35:11546-11546

11546 Background: TRC105, an endoglin-targeting monoclonal antibody with anti-angiogenic and anti-tumor activity, is being evaluated in multiple diseases. Here we report on pharmacodynamic and prognostic biomarkers in patients (pts) treated with both

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c118b483541323be9bccc0cbc930901a
https://doi.org/10.1200/jco.2017.35.15_suppl.11546

Zobrazit plný text záznamu

A phase 2 trial of TRC105 with bevacizumab for bevacizumab refractory glioblastoma

Autor: Manmeet Ahluwalia, Manoj A. Jivani, Charles P. Theuer, Rekha Chaudhary, Lisa Rogers, Herbert B. Newton, Ben K. Seon, Bonne J. Adams, Ronald L. Shazer

Publikováno v: Journal of Clinical Oncology. 34:2035-2035

2035Background: Endoglin is an endothelial cell membrane receptor highly expressed on tumor vessels that is essential for angiogenesis. It is upregulated by hypoxia and VEGF inhibition and may be a...

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::df9cd0decd231450924c353d93ec3c56
https://doi.org/10.1200/jco.2016.34.15_suppl.2035

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání